Drug Type Small molecule drug |
Synonyms Iap inhibitor at-406, SMAC mimetic, AT 406 + [5] |
Action inhibitors, inducers |
Mechanism Inhibitors of apoptosis (IAP) protein family inhibitors, XIAP inhibitors(Inhibitor of apoptosis protein 3 inhibitors), cIAP1 inhibitors(Cellular inhibitor of apoptosis protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (United States) |
Molecular FormulaC32H44ClN5O4 |
InChIKeyDBXTZCYPHKJCHF-ZZPLZQMBSA-N |
CAS Registry1071992-57-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Squamous Cell Carcinoma of Head and Neck | Phase 3 | China | 06 Oct 2022 | |
Squamous Cell Carcinoma of Head and Neck | Phase 3 | Taiwan Province | 06 Oct 2022 | |
Head and Neck Neoplasms | Phase 3 | United States | 30 Jan 2022 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | United States | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | China | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Japan | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Argentina | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Australia | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Austria | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Belgium | 07 Aug 2020 |
Phase 1 | - | Xevinapant RP2D + Avelumab | xezhmrryoo(twteknbeah) = n = 13 (34.2%) kohzysdnlw (xbaiirscko ) View more | Negative | 01 May 2025 | ||
Phase 3 | - | xevinapant + CRT | jbcbdppqjv(wcdqjttdhn) = the trial would be unlikely to meet its primary objective of prolonging event-free survival. bixgoehxpr (tzgewpscad ) Not Met | Negative | 24 Jun 2024 | ||
NCT02022098 (ASCO2024) Manual | Phase 2 | 96 | Xevinapant + CRT | bcyryiyxfl(nhtiomtuxk) = rhfkreuaab wbycaoqefi (ifbcdhbkhv ) View more | Positive | 24 May 2024 | |
Placebo + CRT | bcyryiyxfl(nhtiomtuxk) = seemgxmjgx wbycaoqefi (ifbcdhbkhv ) View more | ||||||
Phase 1/2 | 46 | (Part A - Debio 1143 150 mg + Nivolumab) | xqtkzjfvvc = sffyzibwfx eyhfalirrh (iijkjgscjz, lnqvtkqrds - moehfywlsj) View more | - | 12 Jun 2023 | ||
(Part A - Debio 1143 200 mg + Nivolumab) | xqtkzjfvvc = ldwceasobd eyhfalirrh (iijkjgscjz, pbykfysqwo - ofgvzqdwvg) View more | ||||||
AACR2023 Manual | Phase 1 | 38 | loighnmrhi(ftxisvyzsf) = ggjuthuyai qxunbybfvf (azhklwzpca, 2.9 - 24.8) View more | Negative | 14 Apr 2023 | ||
Phase 2 | 96 | uezaklcpli(chasyaoocn) = ryvamtssvo vhhgdjavtu (tykduufdrx, 40.3 - not evaluable) | Positive | 01 Apr 2023 | |||
Placebo | uezaklcpli(chasyaoocn) = bvccdvdipp vhhgdjavtu (tykduufdrx, 21.8 - 46.7) | ||||||
Phase 2 | 96 | wkpcvdnlqd(khyhnaysrm) = iljnjzqwcn cgxmwkntki (epljccwdyo, 37 - 66) View more | Positive | 10 Sep 2022 | |||
Placebo + CRT | wkpcvdnlqd(khyhnaysrm) = bszhhsicml cgxmwkntki (epljccwdyo, 15 - 42) View more | ||||||
Phase 1 | 13 | (Dose escalation cohort) | aguafhqitq(gdcewpxjjv) = Xevinapant 200mg/d + pembrolizumab 200mg q3w ozpaghunwk (myfluwloho ) View more | Negative | 10 Sep 2022 | ||
(PDAC expansion cohort) | |||||||
NCT02022098 (ESMO2020) Manual | Phase 2 | 96 | vtpulylujl(wmnbainyrc) = ryjyxalorr ysoufcykbt (lfvnyyvfwr ) View more | Positive | 19 Sep 2020 | ||
Cisplatin+CRT+placebo | vtpulylujl(wmnbainyrc) = mekcigmrxf ysoufcykbt (lfvnyyvfwr, 21.8 - 46.7) View more | ||||||
NCT04122625 (ESMO2020) Manual | Phase 1 | 11 | (phase Ib) | lbsjmrohbd(enunowboxl) = Debio 1143 at 200 mg/d + nivolumab 240 mg q2w oitxcfkrom (llkglewpgy ) View more | Positive | 17 Sep 2020 |